Telix Pharmaceuticals completed enrollment in BiPASS, its prostate imaging study, and aligned with the FDA on a U.S. NDA pathway. If approved, the route could support reimbursement as a new product and broaden access to 68Ga-PSMA-PET imaging for a larger patient population.
Key Highlights
- The announcement was issued on September 2, 2026, from Melbourne, Australia.
- Telix Pharmaceuticals completed patient enrollment in its BiPASS study.
- BiPASS evaluates Illuccix and Gozellix with MRI and PSMA-PET/CT before prostate biopsy.
- Telix aligned with the FDA on a potential NDA pathway that could support reimbursement as a new product.
Telix Pharmaceuticals Ltd completed patient enrollment in its BiPASS study, which evaluates prostate cancer imaging before biopsy. The company also aligned with the U.S. Food and Drug Administration on a New Drug Application pathway that, if approved, could support reimbursement as a new product and widen patient access to 68Ga-PSMA-PET imaging.
BiPASS Study Reaches Enrollment Milestone
BiPASS is assessing Telix’s commercial PSMA-PET imaging agents, Illuccix and Gozellix, in the pre-biopsy setting. The study combines MRI with PSMA-PET/CT to evaluate diagnostic performance in detecting prostate cancer before tissue sampling. Telix describes the trial as prospective and open-label, with participation from the U.S. and Australia. The study is intended to determine whether this imaging combination can improve diagnostic accuracy, reduce unnecessary biopsies or help physicians target biopsies more effectively than current practice.
FDA Pathway Targets Reimbursement Access
The FDA alignment concerns a potential U.S. NDA route for BiPASS. Approval would support reimbursement as a new product, according to the announcement, rather than relying on an existing reimbursement pathway. BiPASS therefore links its diagnostic evaluation with a potential regulatory and reimbursement route for the imaging agents.
FAQs
Q: What is the Telix BiPASS study?
A: BiPASS is Telix Pharmaceuticals’ prostate cancer imaging study in the pre-biopsy setting. It evaluates MRI combined with PSMA-PET/CT to assess diagnostic performance before biopsy.
Q: What did Telix align with the FDA on?
A: Telix aligned with the FDA on a U.S. New Drug Application pathway for BiPASS. If approved, the route could support reimbursement as a new product.
Q: Which products are being evaluated in BiPASS?
A: BiPASS evaluates Telix’s Illuccix and Gozellix imaging agents. Both are used with the company’s 68Ga-PSMA-PET approach for prostate cancer imaging.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.